(NASDAQ: INO) Inovio Pharmaceuticals's forecast annual revenue growth rate of 621.32% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 64.17%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.07%.
Inovio Pharmaceuticals's revenue in 2025 is $217,756.On average, 2 Wall Street analysts forecast INO's revenue for 2025 to be $282,154,266, with the lowest INO revenue forecast at $7,333,444, and the highest INO revenue forecast at $556,975,087. On average, 2 Wall Street analysts forecast INO's revenue for 2026 to be $1,256,952,336, with the lowest INO revenue forecast at $363,005,488, and the highest INO revenue forecast at $2,150,899,184.
In 2027, INO is forecast to generate $3,149,530,948 in revenue, with the lowest revenue forecast at $2,152,365,873 and the highest revenue forecast at $4,146,696,023.